IL116831A - Anhydrous crystalline valaciclovir hydrochloride and its preparation - Google Patents

Anhydrous crystalline valaciclovir hydrochloride and its preparation

Info

Publication number
IL116831A
IL116831A IL11683196A IL11683196A IL116831A IL 116831 A IL116831 A IL 116831A IL 11683196 A IL11683196 A IL 11683196A IL 11683196 A IL11683196 A IL 11683196A IL 116831 A IL116831 A IL 116831A
Authority
IL
Israel
Prior art keywords
valaciclovir hydrochloride
valaciclovir
hydrochloride
crystalline form
anhydrous
Prior art date
Application number
IL11683196A
Other languages
English (en)
Other versions
IL116831A0 (en
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL116831(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of IL116831A0 publication Critical patent/IL116831A0/xx
Publication of IL116831A publication Critical patent/IL116831A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
IL11683196A 1995-01-20 1996-01-19 Anhydrous crystalline valaciclovir hydrochloride and its preparation IL116831A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative

Publications (2)

Publication Number Publication Date
IL116831A0 IL116831A0 (en) 1996-05-14
IL116831A true IL116831A (en) 1998-10-30

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11683196A IL116831A (en) 1995-01-20 1996-01-19 Anhydrous crystalline valaciclovir hydrochloride and its preparation

Country Status (40)

Country Link
US (1) US6107302A (cg-RX-API-DMAC10.html)
EP (1) EP0804436B1 (cg-RX-API-DMAC10.html)
JP (1) JP3176633B2 (cg-RX-API-DMAC10.html)
KR (1) KR100376074B1 (cg-RX-API-DMAC10.html)
CN (1) CN1049893C (cg-RX-API-DMAC10.html)
AP (1) AP662A (cg-RX-API-DMAC10.html)
AR (1) AR002270A1 (cg-RX-API-DMAC10.html)
AT (1) ATE302777T1 (cg-RX-API-DMAC10.html)
AU (1) AU702794B2 (cg-RX-API-DMAC10.html)
BG (1) BG63393B1 (cg-RX-API-DMAC10.html)
BR (1) BR9606768A (cg-RX-API-DMAC10.html)
CA (1) CA2210799C (cg-RX-API-DMAC10.html)
CY (1) CY2531B1 (cg-RX-API-DMAC10.html)
CZ (1) CZ297065B6 (cg-RX-API-DMAC10.html)
DE (1) DE69635106T2 (cg-RX-API-DMAC10.html)
DK (1) DK0804436T3 (cg-RX-API-DMAC10.html)
EA (1) EA000364B1 (cg-RX-API-DMAC10.html)
EE (1) EE03528B1 (cg-RX-API-DMAC10.html)
ES (1) ES2248806T3 (cg-RX-API-DMAC10.html)
FI (1) FI973063A7 (cg-RX-API-DMAC10.html)
GB (1) GB9501178D0 (cg-RX-API-DMAC10.html)
GE (1) GEP20001940B (cg-RX-API-DMAC10.html)
HR (1) HRP960024B1 (cg-RX-API-DMAC10.html)
HU (1) HU222993B1 (cg-RX-API-DMAC10.html)
IL (1) IL116831A (cg-RX-API-DMAC10.html)
IN (1) IN182468B (cg-RX-API-DMAC10.html)
IS (1) IS2268B (cg-RX-API-DMAC10.html)
NO (1) NO315558B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ298851A (cg-RX-API-DMAC10.html)
OA (1) OA10499A (cg-RX-API-DMAC10.html)
PL (1) PL182175B1 (cg-RX-API-DMAC10.html)
RO (1) RO118693B1 (cg-RX-API-DMAC10.html)
RS (1) RS49518B (cg-RX-API-DMAC10.html)
SI (1) SI0804436T1 (cg-RX-API-DMAC10.html)
SK (1) SK285329B6 (cg-RX-API-DMAC10.html)
TR (1) TR199700656T1 (cg-RX-API-DMAC10.html)
UA (1) UA46001C2 (cg-RX-API-DMAC10.html)
UY (1) UY25779A1 (cg-RX-API-DMAC10.html)
WO (1) WO1996022291A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA96449B (cg-RX-API-DMAC10.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
DE69726255T2 (de) * 1996-01-19 2004-08-26 Glaxo Group Ltd., Greenford Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
CN1250449A (zh) * 1997-01-17 2000-04-12 味之素株式会社 新型z－伐昔洛韦结晶
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
SK286975B6 (sk) * 2001-02-24 2009-08-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
MXPA04002192A (es) * 2001-09-07 2005-02-17 Teva Pharma Formas cristalinas de clorhidrato de valaciclovir.
EP1453834A1 (en) * 2001-11-05 2004-09-08 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
EP1465894A4 (en) * 2001-11-14 2008-10-08 Teva Pharma SYNTHESIS AND PURIFICATION OF VALACYCLOVIR
AU2003240213A1 (en) * 2002-06-24 2004-01-06 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
WO2004035583A1 (en) * 2002-10-16 2004-04-29 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
AU2003289995A1 (en) * 2002-12-09 2004-06-30 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
US7786302B2 (en) * 2003-05-30 2010-08-31 Eczacibasi-Zentiva Kimyasal Urunler Sanayi Ve Ticaret A.S. Crystalline forms of valacyclovir hydrochloride
EP1638972A2 (en) * 2003-06-02 2006-03-29 Teva Pharmaceutical Industries Limited Novel crystalline forms of valacyclovir hydrochloride
TW200536854A (en) * 2004-01-21 2005-11-16 Teva Pharma Process for the preparation of valacyclovir hydrochloride
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
EP1761535A1 (en) * 2004-06-30 2007-03-14 Teva Pharmaceutical Industries Ltd Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
ATE546451T1 (de) * 2005-05-25 2012-03-15 Lilly Co Eli Cyclopropancarbonsäureester von acyclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
KR101541791B1 (ko) * 2006-05-04 2015-08-04 베링거 인겔하임 인터내셔날 게엠베하 다형태
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
AU2008290582B2 (en) * 2007-08-17 2014-08-14 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20140960A1 (es) * 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20110190322A1 (en) * 2008-08-14 2011-08-04 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR20110103968A (ko) 2008-12-23 2011-09-21 베링거 인겔하임 인터내셔날 게엠베하 유기 화합물의 염 형태
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
MX2012014247A (es) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
ES2934843T3 (es) 2011-07-15 2023-02-27 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
US20140296520A1 (en) * 2011-11-25 2014-10-02 Piramal Enterprises Limited Process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
AU6854694A (en) * 1993-06-10 1995-01-03 Farmhispania Sa Amino acid ester of nucleoside analogues
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
OA10499A (en) 2002-04-10
EA000364B1 (ru) 1999-06-24
AP9701058A0 (en) 1997-10-31
EE9700175A (et) 1998-02-16
IN182468B (cg-RX-API-DMAC10.html) 1999-04-17
PL321326A1 (en) 1997-12-08
CZ229497A3 (en) 1997-12-17
GB9501178D0 (en) 1995-03-08
NO973326L (no) 1997-09-16
SK285329B6 (sk) 2006-11-03
PL182175B1 (pl) 2001-11-30
CY2531B1 (en) 2006-04-12
US6107302A (en) 2000-08-22
WO1996022291A1 (en) 1996-07-25
FI973063L (fi) 1997-09-18
HRP960024B1 (en) 2005-08-31
ATE302777T1 (de) 2005-09-15
FI973063A7 (fi) 1997-09-18
EP0804436B1 (en) 2005-08-24
JPH11503718A (ja) 1999-03-30
HUP9801836A3 (en) 1999-06-28
NZ298851A (en) 1999-01-28
FI973063A0 (fi) 1997-07-18
EP0804436A1 (en) 1997-11-05
BG101833A (bg) 1998-04-30
AU4453996A (en) 1996-08-07
UA46001C2 (uk) 2002-05-15
KR100376074B1 (ko) 2003-06-02
EA199700124A1 (ru) 1997-12-30
JP3176633B2 (ja) 2001-06-18
IL116831A0 (en) 1996-05-14
GEP20001940B (en) 2000-02-05
NO315558B1 (no) 2003-09-22
CA2210799C (en) 2008-06-10
AP662A (en) 1998-08-19
SK96597A3 (en) 1998-02-04
IS2268B (is) 2007-07-15
NO973326D0 (no) 1997-07-18
MX9705462A (es) 1997-10-31
BR9606768A (pt) 1997-12-30
SI0804436T1 (sl) 2006-02-28
IS4527A (is) 1997-07-15
EE03528B1 (et) 2001-10-15
AU702794B2 (en) 1999-03-04
DK0804436T3 (da) 2005-12-27
HRP960024A2 (en) 1997-10-31
UY25779A1 (es) 2000-08-21
YU3396A (sh) 1998-12-23
HUP9801836A2 (hu) 1999-05-28
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
CZ297065B6 (cs) 2006-08-16
RO118693B1 (ro) 2003-09-30
RS49518B (sr) 2006-10-27
AR002270A1 (es) 1998-03-11
DE69635106T2 (de) 2006-06-08
KR19980701525A (ko) 1998-05-15
HU222993B1 (hu) 2004-01-28
DE69635106D1 (de) 2005-09-29
CN1179159A (zh) 1998-04-15
CA2210799A1 (en) 1996-07-25
ZA96449B (en) 1996-08-07
TR199700656T1 (xx) 1998-03-21
ES2248806T3 (es) 2006-03-16

Similar Documents

Publication Publication Date Title
CA2210799C (en) Valaciclovir hydrochloride in anhydrous crystalline form
KR100412298B1 (ko) 콜로이드이산화규소를함유하는발라시클로비르정제
CA2243237C (en) Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
PL194752B1 (pl) Krystaliczna postać VI 5,6-dichloro-2-(izopropyloamino)-1-(ß-L-rybofuranozylo)-1H-benzimidazolu, sposób jej wytwarzania, kompozycja farmaceutyczna zawierająca krystaliczną postać i zastosowanie krystalicznej postaci
HK1003055A1 (en) Guanine derivative
HK1003055B (en) Guanine derivative
MXPA97005462A (en) Derived from guan
HK1002851B (en) Valaciclovir tablets containing colloidal silicon dioxide
MXPA97005459A (en) Valaciclovir tablets containing silicon dioxide color

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees